## 503004944 10/03/2014

EPAS ID: PAT3051544

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
PABLO UMAÑA	12/10/2007
EKKEHARD MÖSSNER	12/10/2007

#### **RECEIVING PARTY DATA**

Name:	GLYCART BIOTECHNOLOGY AG
Street Address:	WAGISTRASSE 18
City:	SCHLIEREN-ZÜRICH
State/Country:	SWITZERLAND
Postal Code:	CH-8952

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	13588269

### **CORRESPONDENCE DATA**

**Fax Number:** (202)371-2540

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (202) 371-2600

Email: sschalle@skgf.com, rrussell@skgf.com, ssmith@skgf.com

Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX PLLC

Address Line 1: 1100 NEW YORK AVENUE, N.W.

Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER:	1975.043000B/SAS/MSS	
NAME OF SUBMITTER:	SCOTT A. SCHALLER	
SIGNATURE:	/Scott A. Schaller #60,167/	
DATE SIGNED:	10/03/2014	

## **Total Attachments: 2**

source=1975.43000B\_Assignment#page1.tif source=1975.43000B\_Assignment#page2.tif

PATENT 503004944 REEL: 033882 FRAME: 0591

#### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Pablo UMAÑA and Ekkehard MÖSSNER, hereby sell and assign to GlycArt Biotechnology AG, a corporation formed under the laws of Switzerland, whose mailing address is Wagistrasse 18, Schlieren-Zürich, Switzerland CH-8952 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same and Uses Thereof for which application(s) for patent in the United States of America has a filing date or a 371(c) date of August 9, 2007 (also known as United States Application No. 11/889,215), in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

Page 1 of 2

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuationin-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 12 / 10 / 2007 Signature of Inventor: Pablo UMAÑA

Date: Dec 10. 2007 Signature of Inventor:

Atty. Docket No. 1975.0430004/TJS/T-M/JJY Appl. No. 11/889,215 737378\_1.DOC

Page 2 of 2